



Celgene Corporation
 Investor Relations Department
 86 Morris Avenue
 Summit, NJ 07901
 United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	87.80
Trade Time:	11:26 AM ET Mar 22, 2018
Change:	-0.51 (-0.578%)
Day Range	87.65 - 89.03
52-Week Range	86.55 - 147.17
Volume	1,834,876

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 6, 2018 [Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy](#)
- Mar 5, 2018 [Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.](#)
- Feb 27, 2018 [Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis](#)
- Feb 27, 2018 [Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Feb 21, 2018 [Celgene Receives Antitrust Clearance for Juno Acquisition](#)

Financials [\[View all \]](#)

- Feb 7, 2018 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)